You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.
The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.
A new study aims to compare the detection performance of Helio Health's circulating tumor DNA assay with that of other screening modalities.
The investment bank said that the company's noninvasive genomic test for melanoma detection could capture a large market currently served by invasive biopsies.
Cernostics offers an assay that analyzes whole-slide digital images with multiplexed fluorescence to help interpret Barrett's esophagus patient biopsies.
The firm also expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million worth of shares of its common stock.
HalioDx's Immunoscore test, which measures host immune response at the tumor site, will be used to select patients for the trial.
The company is developing a blood-based test to detect more than 50 cancer types across all stages and identify a tumor's tissue of origin.
The FDA granted clearance to consumer genetic testing company Ancestry.com for the over-the-counter use of a health risk test for hereditary thrombophilia.
The firm said the financing enables it to progress with the development of an algorithm that would help detect the most common cancers.
The company's stock will now trade on a split-adjusted basis on the Nasdaq after authorization for the split was approved by stockholders.
Thermo Fisher said the assay is the first and, so far, only FDA-approved test of its kind for a targeted treatment for RET fusion-positive NSCLC.
The Medicare Administrative Contractor will cover ctDNA tests if the patient has a personal history of colorectal cancer.
Biocartis noted that it has suspended its partnership with Exact Sciences to develop the Idylla IVD Oncotype Dx Breast Recurrence Score test project due to the pandemic.
The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care.
Created by BloodPAC members, the resource may serve as a set of generic analytical protocols to help define industry standards for developing liquid biopsy tests.
Google Cloud said that the augmented reality microscope would enable access to artificial intelligence models that can help military doctors with cancer detection.
The Australian molecular diagnostics firm had stockholders' equity in excess of $2.5 million as of Aug. 28, in compliance with the Nasdaq listing rule.
The serum-based proteomic test gauges a pre-treatment immune profile that has shown in retrospective studies to identify patients who are likely to respond well to anti-PD-1 therapy.
The UK government said that the funding aims to support faster and more accurate cancer diagnosis and more personalized treatments for patients.